Dr. Cutler on the Examination of Itolizumab in aGVHD

Publication
Video
Supplements and Featured PublicationsUpdates in Acute Graft-Vs-Host Disease
Volume 1
Issue 1

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, director, Adult Stem Cell Transplantation Program, director, Clinical Research, Stem Cell Transplantation, director, Stem Cell Transplantation Survivorship Program, physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the exploration of itolizumab (Alzumab) in acute graft-versus-host disease (aGVHD).

The monoclonal antibody itolizumab targets the CD6 receptor. Patients with aGVHD typically present with high levels of CD6 on activated T cells, Cutler says. CD6 also assists in trafficking lymphocytes to areas of inflammation, Cutler adds. By targeting a CD6 activation marker on T-cells, itolizumab could attack the cells that might be pathologic in aGVHD, Cutler explains.

Researchers hope the addition itolizumab in the frontline setting of aGVHD can improve response rates of standard-of-care corticosteroids, Cutler notes. Furthermore, the addition of itolizumab could help prevent early relapses patients when corticosteroids are tapered, since steroids can be toxic in the acute setting, Cutler says. Minimizing exposure for patients to corticosteroids could benefit long-term survival, Cutler concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD